Blockchain Registration Transaction Record

Clene Releases Q2 2024 Financial Results and Updates on CNM-Au8(R) Programs

Clene (NASDAQ: CLNN) releases Q2 2024 financial results and updates on CNM-Au8(R) programs. Optimism about potential submission of new drug application for ALS and Rett Syndrome treatment.

Clene Releases Q2 2024 Financial Results and Updates on CNM-Au8(R) Programs

This news matters because it provides insight into the progress of a clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases. The updates on CNM-Au8(R) programs for ALS and Rett Syndrome offer hope for patients and their families, with the potential for a new drug application submission later this year.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0xe7f814b04302c236a42d6d565b5f41a3b31d646d24cd66af0422f067aaae35af
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital Fingerprintcoolw2Ls-02f503f5ad926c8424123084faea3c63